Results 101 to 110 of about 18,669 (233)

Changes in Hypertrophic Synovium Status in Adult Patients With Severe Hemophilia A Receiving Emicizumab Prophylaxis: The RESOLVE Study

Haemophilia, EarlyView.
ABSTRACT Background Evidence on the impact of emicizumab on joint health, particularly hypertrophic synovium (HS), remains limited. Objectives To evaluate changes in HS, using point‐of‐care ultrasound and clinical examination in People with Haemophilia (PwH) switching from replacement therapy to emicizumab.
Matteo Nicola Dario Di Minno, Erminia Baldacci, Ilenia Lorenza Calcaterra, Guido D'Errico, Cristina Santoro, Alessandra Strangio, Silvia Sorella, Marzia Leotta, Rita Carlotta Santoro   +8 more
wiley   +1 more source

Proposal of an Integrated Patient Journey roadmap for the introduction of the first gene therapy for haemophilia B in Spain – The BHEMOGEN project

Rare
Background: The approval of the first gene therapy for haemophilia B represents a disruptive innovation in its management. Its practical integration into the Spanish national healthcare system presents unique challenges and opportunities, requiring the ...
MT Álvarez-Román, S Bonanad, C Herrera, MR López, DA García-Diego, S García, JB Montoro, JP Quintero, JL Poveda, A Gil, I Gómez, I Cortés   +11 more
doaj   +1 more source

Quality of life in a large multinational haemophilia B cohort (The B-Natural study) - Unmet needs remain. [PDF]

Haemophilia, 2022
Berntorp E, LeBeau P, Ragni MV, Borhany M, Abajas YL, Tarantino MD, Holstein K, Croteau SE, Liesner R, Tarango C, Carvalho M, McGuinn C, Funding E, Kempton CL, Bidlingmaier C, Cohen A, Oldenburg J, Kearney S, Knoll C, Kuriakose P, Acharya S, Reiss UM, Kulkarni R, Witkop M, Lethagen S, Krouse R, Shapiro AD, Astermark J.   +27 more
europepmc   +1 more source

Living With Factor VII Deficiency—A Mixed Methods Study

Haemophilia, EarlyView.
ABSTRACT Background Factor VII deficiency (FVIID) is a rare autosomal recessive disorder, resulting in potentially unpredictable and life‐threatening bleeding. The prevalence of symptomatic patients is 1 in 300,000. Treatment is mostly given following bleeding, but those with the lowest levels may be offered prophylaxis.
Simon Fletcher, Matthew Boyton, Sam Bristow, Kate Khair   +3 more
wiley   +1 more source

Pattern of Haemarthrosis in Haemophilia

Journal of Rawalpindi Medical College, 2013
Background: To study the pattern of haemarthrosis and its related complications in patients of Haemophilia A and B. Methods: Fifty one patients of Haemophilia A and B were evaluated on the basis of patient`s demographic data, history (family, medication,
Zahida Qasim
doaj  

Efficacy and safety of subcutaneous prophylaxis with dalcinonacog alfa in adults with haemophilia B. [PDF]

Haemophilia, 2021
Mahlangu J, Levy H, Lee M, Del Greco F.
europepmc   +1 more source

Artificial Intelligence and Machine Learning in the Context of Hemophilia: A Scope Review

Haemophilia, EarlyView.
ABSTRACT Introduction Advances in hemophilia treatment have improved life expectancy, yet challenges remain in disease management, predicting clinical complications, and optimizing healthcare resources. Artificial intelligence (AI) and machine learning (ML) have emerged as promising tools to support clinical decision‐making and personalized care ...
Tatyane Oliveira Rebouças, André Cardoso Tavares, Antônio Diego Costa, Cícera Jamille Caldas Rodrigues, Lucilane Maria Sales da Silva   +4 more
wiley   +1 more source

Patient Perspectives in Haemophilia A: Unmet Needs of Individuals Receiving Factor and Non‐Factor Treatments

Haemophilia, EarlyView.
ABSTRACT Introduction There is limited qualitative published real‐world data on treatment patterns among people with severe haemophilia A (PwSHA), particularly those with unmet needs. Aim This qualitative study aimed to explore the impact of taking prophylactic extended half‐life factor VIII (EHL‐FVIII) or emicizumab on psychosocial and physical ...
Nana Kragh, Veruska Carboni, Duygu Bozkaya, Idaira Rodriguez‐Santana, Claudia Mighiu, Bethany Franks, Arnoud Plat, Randall Curtis   +7 more
wiley   +1 more source

IDEAL study: A real-world assessment of pattern of use and clinical outcomes with recombinant coagulation factor IX albumin fusion protein (rIX-FP) in patients with haemophilia B in Italy. [PDF]

Haemophilia, 2023
Tagliaferri A, Molinari AC, Peyvandi F, Coppola A, Demartis F, Biasoli C, Borchiellini A, Cultrera D, De Cristofaro R, Daniele F, Giordano P, Marchesini E, Margaglione M, Marino R, Pollio B, Radossi P, Santoro C, Santoro RC, Siragusa S, Sottilotta G, Tosetto A, Piscitelli L, Villa MR, Zanon E, Finardi A, Schiavetti I, Vaccari D, Castaman G.   +27 more
europepmc   +1 more source

Physical Activity, Bleeding Incidence and Health‐Related Quality of Life, in Patients With Haemophilia A Without Inhibitors, Treated With Emicizumab: A Post‐Hoc Descriptive Analysis of the Power Study Data

Haemophilia, EarlyView.
Matteo Nicola Dario Di Minno, Berardino Pollio, Ezio Zanon, Gaetano Giuffrida, Sara Bendinelli, Raffaella Perrone, Giancarlo Castaman, the POWER study sites group   +7 more
wiley   +1 more source